These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 17597017)

  • 1. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
    Stepan JJ; Burr DB; Pavo I; Sipos A; Michalska D; Li J; Fahrleitner-Pammer A; Petto H; Westmore M; Michalsky D; Sato M; Dobnig H
    Bone; 2007 Sep; 41(3):378-85. PubMed ID: 17597017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.
    Dobnig H; Stepan JJ; Burr DB; Li J; Michalská D; Sipos A; Petto H; Fahrleitner-Pammer A; Pavo I
    J Bone Miner Res; 2009 Dec; 24(12):1998-2006. PubMed ID: 19453263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
    Allen MR; Iwata K; Phipps R; Burr DB
    Bone; 2006 Oct; 39(4):872-9. PubMed ID: 16765660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmenopausal osteoporosis and alendronate.
    Pérez-López FR
    Maturitas; 2004 Jul; 48(3):179-92. PubMed ID: 15207883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Age-related and menopause-related changes of urinary excretion of C- and N-terminal cross-linked telopeptides of type I collagen and the relationships thereof with menopause-related bone loss].
    Liu SP; Liao EY; Wu XP; Cao XZ; Shan PF; Su X
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):371-5. PubMed ID: 16677543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
    Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Density and structural changes in the bone of growing rats after weekly alendronate administration with and without a methotrexate challenge.
    Spadaro JA; Damron TA; Horton JA; Margulies BS; Murray GM; Clemente DA; Strauss JA
    J Orthop Res; 2006 May; 24(5):936-44. PubMed ID: 16609966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
    Roschger P; Lombardi A; Misof BM; Maier G; Fratzl-Zelman N; Fratzl P; Klaushofer K
    J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis.
    Ruan XY; Jin FY; Liu YL; Peng ZL; Sun YG
    Chin Med J (Engl); 2008 Jul; 121(13):1155-8. PubMed ID: 18710630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.
    Chapurlat RD; Arlot M; Burt-Pichat B; Chavassieux P; Roux JP; Portero-Muzy N; Delmas PD
    J Bone Miner Res; 2007 Oct; 22(10):1502-9. PubMed ID: 17824840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.
    Allen MR; Burr DB
    J Bone Miner Res; 2007 Nov; 22(11):1759-65. PubMed ID: 17663638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.
    Mashiba T; Hui S; Turner CH; Mori S; Johnston CC; Burr DB
    Calcif Tissue Int; 2005 Sep; 77(3):180-5. PubMed ID: 16265598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.